WallStSmart

BrightSpring Health Services, Inc. Common Stock (BTSG)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 294% more annual revenue ($56.69B vs $14.37B). NVS leads profitability with a 22.5% profit margin vs 2.5%. NVS trades at a lower P/E of 20.7x. BTSG earns a higher WallStSmart Score of 55/100 (C).

BTSG

Buy

55

out of 100

Grade: C

Growth: 8.7Profit: 5.0Value: 4.0Quality: 6.0
Piotroski: 5/9Altman Z: 2.59

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BTSG.

NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$137.16

$43.87 premium

UndervaluedFair: $93.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTSG2 strengths · Avg: 9.0/10
EPS GrowthGrowth
196.6%10/10

Earnings expanding 196.6% YoY

Revenue GrowthGrowth
23.0%8/10

Revenue surging 23.0% year-over-year

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

BTSG4 concerns · Avg: 2.8/10
Profit MarginProfitability
2.5%3/10

2.5% margin — thin

Operating MarginProfitability
3.4%3/10

Operating margin of 3.4%

Debt/EquityHealth
1.173/10

Elevated debt levels

P/E RatioValuation
54.2x2/10

Premium valuation, high expectations priced in

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BTSG

The strongest argument for BTSG centers on EPS Growth, Revenue Growth. Revenue growth of 23.0% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : BTSG

The primary concerns for BTSG are Profit Margin, Operating Margin, Debt/Equity. A P/E of 54.2x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

BTSG profiles as a growth stock while NVS is a value play — different risk/reward profiles.

BTSG carries more volatility with a beta of 1.85 — expect wider price swings.

BTSG is growing revenue faster at 23.0% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

BTSG scores higher overall (55/100 vs 51/100) and 23.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BrightSpring Health Services, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

BrightSpring Health Services, Inc. (BTSG) is a leading provider of home and community-based health services, focusing on diverse patient populations, including individuals with intellectual and developmental disabilities and those in need of rehabilitation support. The company prioritizes personalized, high-quality care, facilitated by a dedicated and skilled workforce that significantly improves patient outcomes and quality of life. With robust investments in innovative technologies and a strong commitment to value-based care, BrightSpring is well-positioned to capitalize on growth opportunities within the dynamic healthcare landscape, highlighting its potential for sustainable, long-term success.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?